Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Etomoxir

From Bioblast
Revision as of 13:17, 12 February 2021 by Spitzer Gudrun (talk | contribs) (replaced FW by M and added units g*mol-1)


high-resolution terminology - matching measurements at high-resolution


Etomoxir

Description

Etomoxir (Eto; 2[6(4-chlorophenoxy)hexyl]oxirane-2-carboxylate) is an irreversible inhibitor of carnitine palmitoyltransferase-1 (CPT-1) on the outer face of the inner mitochondrial membrane. Eto inhibits the transport of the long-chain fatty acids from the cytosol into the mitochondrial matrix, thereby blocking the formation of acyl carnitines in the cytosol, leading finally to inhibition of the fatty acid oxidation. Of note, in contrast to long-chain fatty acids, the transport of short- and medium chain fatty acids is carnitine-independent. The commercially available white compound is soluble in water.

Abbreviation: Eto

File:Etomoxir structure

Application in HRR

Eto (Etomoxir): ((+)-Etomoxir sodium salt hydrate); Sigma Aldrich; E-1905; storage: 2-8 °C; M = 338.76 g·mol-1
Caution: Store tightly sealed, protected from exposure to light. Acute toxicity (oral, dermal, inhalation). Dust mask or eyeshields, faceshields and gloves are recommended by the preparation.
Preparation of 10 mM stock solution (dissolved in H2O):
  1. Weigh 5 mg etomoxir.
  2. Add 1.476 mL dt H2O.
  3. Divide into 500 µL portions.
  4. Store frozen at -20 °C.

MitoPedia topics: Inhibitor